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Rodent Herpesvirus Peru Encodes a Secreted Chemokine Decoy
Receptor
Olga Y. Lubman,a Marina Cella,a Xinxin Wang,a Kristen Monte,c Deborah J. Lenschow,c Yina H. Huang,a* Daved H. Fremonta,b
‹Departments of Pathology & Immunology,a Biochemistry & Molecular Biophysics,b and Medicine,c Washington University School of Medicine, St. Louis, Missouri, USA
Viruses have long been studied not only for their pathology and associated disease but also as model systems for understanding cellular
and immunological processes. Rodent herpesvirus Peru (RHVP) is a recently characterized rhadinovirus related to murine gammaher-
pesvirus 68 (MHV68) and Kaposi’s sarcoma-associated herpesvirus (KSHV) that establishes acute and latent infection in laboratory
mice. RHVP encodes numerous unique proteins that we hypothesize might facilitate host immune evasion during infection. We report
here that open reading frame (ORF) R17 encodes a high-affinity chemokine binding protein that broadly recognizes human and mu-
rine CC and C chemokines. The interaction of R17 with chemokines is generally characterized by rapid association kinetics, and in the
case of CCL3, CCL4, CCL5, CCL24, and XCL1, extremely stable complexes are formed. Functionally, R17 potently inhibited CCL2-
driven chemotaxis of the human monocytic cell line THP-1, CCL3-driven chemotaxis of peripheral blood mononuclear cells, and
CCL2-mediated calcium flux. Our studies also reveal that R17 binds to glycosaminoglycans (GAGs) in a process dependent upon two
BBXB motifs and that chemokine and GAG binding can occur simultaneously at distinct sites. Collectively, these studies suggest that
R17 may play a role in RHVP immune evasion through the targeted sabotage of chemokine-mediated immune surveillance.
Rodent herpesvirus Peru (RHVP) was originally isolated from alung homogenate of a pygmy rice rat (Oligoryzomys microtis)
trapped in Peru (1). RHVP can establish latent infection in B6 and
129 mice, with lethal infections observed in mice lacking inter-
feron responses and/or B and T cells (1). The genome of RHVP
carries all of the conserved open reading frames (ORFs) found in
other rhadinoviruses, such as murine gammaherpesvirus 68
(MHV68) and Kaposi’s sarcoma-associated herpesvirus (KSHV),
as well as at least 18 unique ORFs that are not broadly conserved
among other gammaherpesviruses (1–3). To date, the only func-
tionally characterized protein encoded by RHVP is R12 (pK3), a
transmembrane ubiquitin ligase similar to those found in MHV68
and KSHV that downregulates major histocompatibility complex
class I (MHC-I) surface expression in a unique manner (4). Se-
quence analysis of RHVP R5, R6, R7, R17, and R18 is consistent
with them encoding secreted, extracellular proteins; all contain
leader peptides and lack both transmembrane regions and intra-
cellular localization motifs. Our key hypothesis was that these se-
creted proteins function to subvert host defense.
Most of the damage inflicted on virally infected cells is the
result of activities initiated by proinflammatory cytokines, such as
interleukin 1 (IL-1), tumor necrosis factor alpha (TNF-), and the
interferons. Not surprisingly, these and related factors are favorite
targets for viral sabotage (5–7). An immune evasion strategy com-
monly employed by large-DNA viruses is based on the secretion of
high-affinity binding proteins that act as cytokine scavengers (8,
9). Frequently, these decoy receptors correspond to soluble ver-
sions of their host cellular counterparts. For example, orthopox-
viruses encode a secreted protein with25% sequence similarity
to mammalian gamma interferon (IFN-) receptors that binds
and functionally inhibits IFN- (10, 11). The gammaherpesvirus
Epstein-Barr virus (EBV) encodes a secreted decoy that binds col-
ony-stimulating factor 1 (CSF-1), impairing macrophage differ-
entiation, function, and survival (12).
The role of chemokines in orchestrating host defenses is well
established, with one hallmark being the establishment of concen-
tration gradients that guide immune responder cells toward sites
of infection (13). A wide variety of secreted chemokine binding
proteins with the ability to subvert chemokine signaling have been
identified, including those encoded by schistosoma parasites,
bloodsucking ticks, and herpes- and poxviruses (8, 9). The M3
protein of MHV68 is abundantly secreted during infection and is
capable of promiscuously sequestering members of all four
chemokine classes with subnanomolar affinities. Functional and
structural studies indicate that M3 potently blocks chemokine re-
ceptor interactions by competitive inhibition and disrupts
chemokine gradients by electrostatically mimicking glycosamino-
glycans (GAGs) (14, 15). Other reported herpesvirus proteins that
bind chemokines include the human cytomegalovirus (HCMV)-
encoded pUL21.5 decoy receptor that has exquisite specificity for
human CCL5, binding with high affinity and effectively blocking
chemokine receptor activation (16). In contrast to the chemokine
decoy receptors encoded by MHV68 and HCMV, the herpes sim-
plex virus 1 (HSV-1)- and HSV-2-encoded gG protein appears to
bind chemokines via their GAG binding regions and has been
reported to enhance chemotaxis, perhaps to recruit cells pertinent
to viral infection or spread (17).
Poxviruses encode a number of distinct chemokine binding
proteins. The first group characterized has been termed vCCI
(also called M-T1/35k/vCKBP) and refers to abundantly secreted
glycoproteins expressed early during viral infection that bind se-
lectively to CC and some CXC chemokines with high affinity (0.03
to 100 nM), blocking their activity (18–21). The second group
includes vaccinia A41 and ectromelia E163, which are structurally
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similar to vCCI but appear mechanistically distinct. Chemokine
mutational analysis was used to demonstrate that A41 binds di-
rectly to the GAG recognition regions of chemokines; however,
these proteins are ineffective in blocking chemotaxis (22, 23). In
addition to blocking chemokine-GAG interactions, E163 itself can
tightly associate with GAGs (23). Thus, it appears that these pox-
virus proteins may modulate chemokine networks through the
disruption of chemokine gradients rather than the competitive
inhibition of chemokine receptor binding (22, 23). Although dis-
tinct from A41 and E163, myxoma virus encodes M-T7, a secreted
glycoprotein that functions both as a species-specific inhibitor of
rabbit IFN- and as a chemokine binding protein (21). Another
group of poxvirus-encoded chemokine binding proteins that have
been characterized are termed SECRET domains (24). Chemo-
kine binding studies of the SECRET domains from variola, ec-
tromelia, and cowpox suggest that all of these decoy receptors
bind a similar set of chemokines with low nanomolar affinities,
including both human and mouse CCL28, CCL25, CXCL12b,
CXCL13, and CXCL14 and the mouse chemokines CCL27 and
CXCL11. Further, the binding of SECRET domains to the murine
chemokine CCL25 was shown to block chemotaxis (24), suggest-
ing that the function of these proteins may be more similar to
vCCI discussed above rather than A41 that blocks only chemo-
kine-GAG interactions.
Poxvirus vCCIs are thought to be involved in regulating in-
flammation during acute infection. Myxoma viruses deficient in
M-T1(vCCI) have a subtle phenotype, with an increase in leuko-
cyte infiltration but no significant difference in disease progres-
sion or mortality (18, 25). In addition, mouse studies of ORF virus
infection, a zoonotic parapoxvirus, shown to encode vCCI-like
chemokine binding protein (26), demonstrated that ORF virus
(ORFV) vCCI blocks the recruitment of immature and mature
dendritic cells to the skin and lymph nodes and inhibits T cell
responsiveness in lymph nodes (26, 27). The role of herpesvirus-
encoded chemokine binding proteins in pathogenesis and im-
mune modulation remains poorly understood, in part due to lack
of the appropriate experimental host. For example, inactivation of
M3 expression (by insertion of a translational stop codon) has no
apparent consequence on MHV68 infection following intranasal
inoculation of C57BL/6 mice (28). Intracerebral injection of the
same M3 mutant virus does lead to an altered inflammatory re-
sponse, with higher numbers of infiltrating lymphocytes and mac-
rophages than observed following inoculation with the wild-type
virus (28). However, M3 contributes significantly to MHV68
pathogenesis in a natural host, wood mice, where lack of M3 re-
sulted in substantially reduced latency in the spleen and lung (29,
30).
Despite genetic similarity with MHV68, we have been unable
to identify a protein with sequence similarity to the M3 chemo-
kine decoy receptor in the RHVP genome. However, given the
recurrence of chemokine binding proteins encoded by diverse
large-DNA viruses, we hypothesized that RHVP acquired an alter-
native approach for disrupting chemokine-induced infiltration of
inflammatory cells. Herein, we have examined five secreted pro-
teins encoded by RHVP with the hypothesis that one or more
would function as a cytokine decoy receptor. Using cytokine ar-
rays as a screen, we identified R17 as a potential chemokine bind-
ing protein. Indeed, R17 binds members of two of the four chemo-
kine families (CC and C), with ligand binding characterized by
nanomolar affinities. We show that engagement of chemokines by
R17 blocks their ability to signal through host chemokine receptors
and thereby disrupts chemotaxis. We also found that R17 can en-
hance the association of chemokines with cell surfaces, an observa-
tion that we demonstrate is due to the ability of R17 to bind GAGs.
MATERIALS AND METHODS
Ethics statement. Blood from healthy donors was collected at a leu-
kapheresis center and used according to the guidelines of the Washington
University Medical Center Human Studies Committee. Peripheral blood
mononuclear cells (PBMCs) were isolated using leukoreduction cham-
bers (Trima Accel). This protocol was approved by the Research Ethics
Committee and Human Research Protection Office (HRPO) of Washing-
ton University, School of Medicine. Since leukoreduction chambers are
normally discarded and are stripped of any personal information, the
HRPO determined that informed consent was not necessary.
Cloning, expression, and purification of RHVP-encoded proteins.
The SignalP 4.1 server predicted the following signal peptide cleavage sites
for the secreted proteins of interest: R5 (UnitPro E9M5I4) between Ser 50
and Val 51, R6 (UnitPro E9M5I5) between Gly 22 and Phe 23, R7 (Unit-
Pro E9M5I7) between Ala 18 and Arg 19, R17 (UnitPro E9M5R0) between
Cys 27 and Gly 28, and R18 (UnitPro E9M5R1) between Gly 14 and Gln
15. Mature forms of R5, R6, R7, R17, and R18 ORFs without leader pep-
tide were amplified from RHVP virus genomic DNA (accession number
NC_015049) and cloned into mammalian expression vector pHLsec (In-
vitrogen) in frame with the CD33 leader peptide sequence MPLLLLLPL
LWAG as either C-terminal Fc fusion or C-terminal 8-His fusion pro-
teins. Fc fusion proteins were used in the Bio-Plex cytokine arrays (Fig. 1).
All other assays were performed using R17-His. In this expression vector,
the desired gene is under the control of a CMV promoter with a multiple
cloning site and an SV40 poly(A) signal. This plasmid carries the origin of
replication (oriP) and expresses the EBNA-1 protein from the Epstein-
Barr virus that allows long-term episomal maintenance and translocation
of the plasmid into the nucleus to enhance protein expression. All con-
structs were transiently expressed in HEK293F cells in suspension using
293fectin (Invitrogen) as a transfection reagent and grown in Invitrogen’s
serum-free FreeStyle medium. The culture medium was collected 10 days
after transfection, and RHVP-carried ORFs were purified by standard
protein A affinity chromatography in accordance with the manufacturer’s
protocol (GE Healthcare, Piscataway, NJ) and were subsequently buffer
exchanged into phosphate-buffered saline (PBS). The R17 C-terminal
8-His fusion construct was purified using Ni-agarose beads (Qiagen, Va-
lencia, CA), followed by size exclusion chromatography (SEC) on a Hi-
Load 26/60 Superdex 200 column (GE Healthcare). SDS-PAGE and West-
ern blot analysis confirmed protein purity. Two additional variants of R17
were used in this study: R17 mutant, where residues 29 to 32 of the mature
sequence RKDR (BBXB) were mutated to EDDE and are referred to as
R17GAG1 and residues 333 to 337 of the mature sequence KGRRK
(BXBBB) were mutated to DGEED and are referred to as R17GAG2. Mu-
tagenesis was performed using a multisite QuickChange mutagenesis kit
(Agilent Technologies) on the background of the wild-type R17 C-termi-
nal His construct and verified by DNA sequencing. The identity of R17
was confirmed by N-terminal sequencing (Midwest Analytical, Saint
Louis, MO).
Bio-Plex cytokine arrays. Customized Bio-Plex pro arrays (Bio-Rad)
were ordered to detect murine IL-6, IL-1, IL-10, IL-12p70, IL-13, IFN-,
CCL2, CCL3, CCL5, and TNF-. The assay was run per the manufactur-
er’s guidelines, with the exception that recombinant RHVP Fc fusion pro-
teins were preincubated with the recombinant standards for 20 min prior
to the addition to the assay plate. In brief, the antibody-coupled beads of
the 10 analytes were prepared in assay buffer and then placed in each well
of the assay plate. The recombinant standards were diluted as outlined in
the manufacturer’s guidelines, and the standard was then diluted 1:3 to
generate a standard curve. After the standards were diluted, 150l of PBS,
R17-Fc, or R6-Fc was added to each of the standards and incubated for 20
min at room temperature. The standards were then added to each well and
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incubated on a shaker at room temperature for 30 min. The plate was
washed 3 times, and then detection antibody was added and incubated on a
shaker for 30 min at room temperature. The plate was again washed 3 times,
and then streptavidin-PE was added to each well and incubated on a shaker at
room temperature for 10 min. After the plate was washed 3 times, 125 l of
assay buffer was added to each well, and the plate was read on a Bio-Plex plate
reader system using Bio-Plex Manager software for analysis.
Recombinant chemokines. Murine CCL2 and CCL3 chemokines
were expressed in Escherichia coli, refolded from inclusion bodies, and
purified as previously described (31). All chemokines except for murine
CCL2 and CCL3 were purchased from Peprotech. Biotinylation of
chemokines was performed using EZ-Link N-hydroxysuccinimide
(NHS)–polyethylene glycol 4 (PEG4)– biotin (Thermo Scientific) using a
2:1 molar ratio of biotin to chemokines. Unbound biotin was removed
using Thermo Scientific Zebra spin desalting columns per the manufac-
turer’s instruction.
SPR binding analysis. Surface plasmon binding (SPR) was used to
directly measure the affinity and kinetics of chemokine binding by R17
and its variants. R17, R17GAG1, and R17GAG2 were immobilized on a CM5
chip (GE Healthcare) using standard amine coupling chemistry (Biacore
amine coupling kit) to a level of 200 to 500 response units (RU) for kinetic
binding analysis and 1,000 RU for equilibrium binding analysis using a
Biacore T-100 biosensor (GE Healthcare). A control flow cell was pre-
pared by coupling non-chemokine binding protein R7 or NeutrAvidin to
the chip at a similar level. Experiments were performed at 100l/min and
25°C using HBS-EP (10 mM HEPES [pH 7.5], 150 mM NaCl, 3 mM
EDTA, 0.005% Tween 20) as a running buffer. High flow rates and low
levels of coupled proteins were used to minimize the effects of mass trans-
port. For all kinetic experiments, 358 l of chemokine was injected over
experimental and control flow cells followed by a 500-s period to monitor
dissociation before regeneration was achieved by injecting 100l of 0.1 M
glycine (pH 2.0). Each experiment was performed at a minimum of three
times with eight different chemokine concentrations followed by three
buffer injections. The association (Ka) and the dissociation (Kd) values
were determined simultaneously by globally fitting sensograms for an
entire range of chemokine concentrations to a 1:1 mass transport model
with BIAevaluation software. This global analysis was performed inde-
pendently for each series of concentrations, the resulting values were av-
eraged, and the standard deviation was calculated to reflect the experi-
mental error. Apparent equilibrium dissociation constants were
determined either from the kinetic values using the equation KD,kin 
Kd/Ka or from saturation binding experiments, KD,eq  RU response/
chemokine concentration.
Chemotaxis assay. THP-1 cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyru-
vate, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glu-
tamine. Cell culture was maintained between 2 105 and 9 105 cells/ml
at 37°C with 5% CO2. PBMCs were isolated from heparinized blood by
Ficoll gradient centrifugation (GE Biosciences) and resuspended in RPMI
1640 medium supplemented with 1% bovine serum albumin (BSA).
Ninety-six-well Transwell permeable support inserts (Corning Costar;
Sigma-Aldrich) were used. Human CCL2 and CCL3 at concentrations of
10 nM were diluted in 1% BSA RPMI and placed in the lower compart-
ment, and 6 104 of either human THP-1 monocytes or 1 105 human
PBMCs were placed in the upper chamber, separated by a 5-m-pore-size
filter. After PBMCs were incubated for 3 h and the THP-1 cells for 4 h at
37°C, the cells in the lower chamber were spun, lysed, and counted using
CyQuant dye (Life Technologies). For competition experiments, three
proteins, R17, M3, and R7, were added to the lower chamber to a final
concentration of 100 nM. The bacterially refolded purified M3 was used as
a positive control for inhibition, while R7 was used as a negative control
for inhibition.
Calcium mobilization assays. THP-1 cells were incubated at a density
of 5 106 cells/ml in Ca2	 buffer with 1 M Fura-2AM loading dye and
0.02% pluronic at 37°C for 30 min in the dark before being washed twice
and resuspended at 5  106 cells/ml in Ca2	-free buffer. Fura-2-loaded
cells were transferred into a poly-L-lysine-treated 96-well assay plate at
5  105 cells/well for CCL2 stimulation. A total of 160 nM CCL2 was
preincubated with buffer control, 2M R17, 2M MR1 (32), or 1M M3
for 5 min at 37°C prior to cell stimulation. Ca2	 response was measured
on a FlexStation system from Molecular Devices based on the spectrofluo-
rimetry at 37°C.
Competition of chemokine binding to cells. To evaluate CCL2,
CCL3, and CCL5 binding to CHOK1 and CHO745 cells, chemokines and
a negative-control protein (MR1) (32) were nonspecifically biotinylated
using the EZ-biotin kit (Pierce) using a 2:1 biotin-to-protein molar ratio,
followed by removal of unbound biotin (Thermo Scientific Zebra desalt-
ing columns). CHOK1 and CHO745 cells were maintained in F-12 me-
dium supplemented with 10% fetal calf serum (FCS) and 100 Penn-
Strep. On the day of the experiment, cells were washed once with PBS,
FIG 1 R17 pages interaction of chemokines with specific antibodies. Purified R17 (1 M) and purified R6 (1 M) were preincubated with serial dilutions of
recombinant cytokine standards prior to the addition to a Bio-Plex plate. The recombinant standards were diluted as outlined in the manufacturer’s guidelines,
and the standard was then diluted 1:3 to generate a standard curve. R17 inhibited the detection of mCCL2, mCCL3, and mCCL5 by chemokine-specific antibodies
but had no effect on the interaction of IL-6, TNF-, or IL-1 with their cognate antibodies.
Lubman et al.
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detached using 0.2% EDTA, and resuspended in staining buffer contain-
ing PBS, 0.5% BSA, and 2 mM EDTA. Biotinylated chemokines were
added to cells to a final concentration ranging from 50 to 250 nM, incu-
bated for an hour on ice, washed twice, and detected with streptavidin PE
(Life Technologies) using flow cytometry. To determine the effect of R17,
R17GAG1, and R17GAG2 on CCL2-, CCL3-, and CCL5-GAG interaction,
0.1 to 0.5 M of R17 or R17GAG1 or R17GAG2 was precomplexed with
biotinylated chemokines and incubated with both CHOK1 and CHO745
cells. As a positive control for inhibition, bacterially refolded M3 was used.
Flow cytometry was undertaken using a FACS array or FACSCalibur, and
data were analyzed using FlowJo software.
R17 binding to cells. R17, R17GAG1, and R17GAG2 were nonspecifically
biotinylated using the EZ-biotin kit (Pierce) using a 2:1 biotin-to-protein
molar ratio, followed by removal of unbound biotin (Thermo Scientific
Zebra desalting columns), and added to CHOK1 and CHO745 to a final
concentration of 0.2 M in the same manner as described in the section
above.
RESULTS
Production of five secreted proteins uniquely encoded by
RHVP. We began our studies of RHVP by examining the genome
for the presence of novel ORFs encoding proteins that may be
secreted during viral infection. Five hypothetical proteins were
identified that contain an N-terminal signal peptide but lack any
apparent transmembrane regions or intracellular retention motifs
(R5, R6, R7, R17, and R18). Analysis of these RHVP protein se-
quences using the fold recognition server PHYRE2 (33) indicates
that R5, R7, and R18 likely are all composed of four tandem Ig
domains, while positively charged R6 might fold as a helical bun-
dle. The sequence of R17 produced no significant hits using this
analysis, although we note that the protein is predicted to have a
low isoelectric point (pI 5.7), a common feature among previ-
ously identified chemokine binding proteins (15, 20). The mature
sequences of all five ORFs were amplified from RHVP genomic
DNA (with endogenous signal peptides removed) and cloned into
the mammalian expression vector pHLsec in frame with the CD33
signal peptide as either C-terminal Fc or His tag fusion proteins.
Constructs were transiently expressed in HEK293F cells, and the
secreted RHVP proteins were purified by standard chromatogra-
phy methods.
Screening of cytokine binding by RHVP-encoded proteins.
Our initial approach toward identifying functions for R5, R6, R7,
R17, and R18 involved screening of a panel of cytokines using
Bio-Plex cytokine arrays (Bio-Rad). These arrays were originally
designed to test for the presence of cytokines in cell culture me-
dium using cytokine-specific antibodies (34). In our experiments,
soluble RHVP Fc fusion proteins (1 M) were premixed with
select murine cytokine standards, and competition with the bead-
coupled detection antibodies was assessed. As seen in Fig. 1, serial
dilution of IL-6, TNF-, or IL-1 in the presence of either R6 or
R17 did not affect the cytokine-antibody interaction. However,
serial dilutions of CCL2, CCL3, or CCL5 in the presence of R17
but not in the presence of R6 inhibited the ability of these chemo-
kines to bind their respective antibodies (Fig. 1). Fc fusion pro-
teins of R5, R7, and R18 also did not disrupt chemokine-antibody
interactions, and none of the examined RHVP proteins appeared
to block specific antibody detection of IL-10, IL-12p70, IL-13, or
IFN- (data not shown). Thus, the Bio-Plex screen uniquely iden-
tified RHVP R17 as a potential chemokine binding protein.
R17 binds CC and C family chemokines with high affinity. To
assess the ability of R17 to directly interact with chemokines, we
have screened a large panel of different chemokines and cytokines
using surface plasmon resonance (SPR) (Fig. 2). In these experi-
ments, R17 was covalently coupled to a BIAcore CM5 chip and
FIG 2 R17 binds CC and C chemokines with high affinity. (A and B) SPR sensograms of mCCL12 and hCCL2 binding to CM5 chip immobilized R17. The
experimental curves (gray lines) are globally fit using a 1:1 mass transport model (black lines) to determine kinetic parameters. (C) Shown is a representative
response curve for the saturation binding analysis of mCCL3 to R17, which cannot be accurately globally fit. (D) Saturation curve and Scatchard plot for the
binding of mCCL3 to R17. (E) Tabulation of the interaction parameters for human and murine chemokines binding to R17. Reported values for Ka, Kd, and
KD,kinKd/Ka are derived from globally fit binding analysis as means
 standard deviations. Reported values forKD,eq are derived from Scatchard analysis of the
saturation binding analysis as means 
 standard deviations. The following cytokines were tested, and no binding was observed under the same experimental
conditions: mCCL21, mCXCL8, mCXCL10, mCXCL9, mCXCL2, mCXCL12, mCXCL1, CX3C, mIL-13, mIL-12, mIL-6, mIL-17, mTNF-.
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examined for specific ligand binding. C-terminal Fc or His was not
used for immobilization, because highly charged chemokines
nonspecifically interact with antibodies necessary to capture pro-
teins either by Fc or His tag. Of the 25 mouse and human chemo-
kines tested, a concentration-dependent increase in the refractive
index together with saturable binding was observed for mCCL2
and hCCL2, for mCCL3 and hCCL3, for mCCL4, mCCL5 and
hCCL5, and for mCCL8, mCCL11, mCCL20, mCCL24, mCCL19,
mCCL12, and mXCL1. As negative controls for chemokine bind-
ing, we used either a NeutrAvidin-coupled chip or RHVP R7; both
of these proteins lack chemokine binding activity. From the SPR
experiments, we have determined that R17 directly interacts with
all of the CC chemokines we tested except mCCL21, a chemokine
expressed constitutively in secondary lymphoid tissues and
thought to be essential for cell migration into lymphoid organs
(35, 36). We have also determined that R17 binds the C chemo-
kine lymphotactin (XCL1). In contrast, R17 did not interact with
any of the CXC chemokines we examined (mCXCL8, mCXCL10,
mCXCL9, mCXCL2, mCXCL12, mCXCL1) or the CX3C chemo-
kine fractalkine. SPR binding studies with other murine cytokines
(IL-13, IL-12, IL-6, IL-17, TNF-) did not reveal any additional
R17 ligand binding specificities. Among the chemokines that R17
binds, the apparent complex half-lives (t1/2) vary considerably.
For example, mouse and human versions of CCL2, CCL9, CCL12,
and CCL20 all form complexes with measurable off rates (t1/2
varying from 2 to 32 s), and we report in Fig. 2E equilibrium and
kinetic binding parameters which generally are in agreement. In
contrast, CCL3, CCL4, CCL5, and XCL1 form stable complexes
with extremely slow dissociation rates that appear to be in excess
of 10 min (Fig. 2). Quantitative kinetic characterization of the
latter chemokines could not be measured accurately due to mass
transport limitations during the association phase and lack of an
appropriate competitor to speed up the dissociation phase. We
therefore report apparent KD,eq values determined from satura-
tion binding analysis for these chemokines (0.1 to 4 nM), although
the actual affinities may well be picomolar.
R17 blocks chemokine-mediated cell migration. Based on the
known mechanisms of viral immune evasion, we hypothesized
that R17 may function as a viral decoy that prevents chemokine
recruitment of immune cells to sites of infection (8). To address
the functional consequences of R17-chemokine interactions, we
performed experiments evaluating the migration of the human
monocytic cell line THP-1 in response to hCCL2, a fast dissociat-
ing R17 ligand (KD,eq 12 nM, t1/2 2.1 s), and human PBMCs in
response to hCCL3, a slow off-rate R17 ligand (KD,eq  1.4 nM,
t1/2,app 1,000 s). We found that R17 potently blocked THP-1 cell
transmigration when incubated in 10-fold molar excess of CCL2
(Fig. 3A). Similar disruption was observed when we incubated
CCL2 with the M3 decoy receptor encoded by MHV68, which was
previously shown to effectively block cell migration mediated by
FIG 3 R17 blocks CC chemokine-mediated transmigration and receptor signaling. Transmigration of either THP-1 cells stimulated with hCCL2 (A) or human
PBMCs stimulated with CCL3 (B) in the presence and absence of R17, M3 (positive control), and R7 (negative control). Different complexes were formed by
incubating 10 nM hCCL2 with 100 nM R7, M3, or R17 at room temperature for 30 min and added to the bottom of a transmigration plate. A total of 6 104
THP-1 cells or 1 105 PBMCs were added to the top of Transwell inserts. The transmigration plates were incubated at 37°C for 4 h for THP-1 chemotaxis and
3 h for PBMC chemotaxis. The cells that migrated from the Transwell insert to the bottom of transmigration plates were pelleted and counted using CyQuant dye.
Standard deviations represent averages from at least three independent experiments. (C) Shown are the changes in relative fluorescence of Fura-2-loaded cells
(ratio of 340 to 380), which monitors the intracellular Ca2	 concentrations. THP-1 cells were stimulated for 30 s with hCCL2 (160 nM) either alone or in
complex with the following proteins: negative-control MR1 (2 M), positive-control M3 (1 M), and R17 (2 M). Ca2	 flux from the endoplasmic reticulum
(ER) was measured for 400 s, followed by the addition of 1 mM Ca2	 to measure influx. Data are representative of at least three separate experiments.
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CCL19 and CCL21 (37). As a negative control, we used RHVP R7
that lacks chemokine binding activity. Similar results were ob-
tained when we examined the ability of R17 to disrupt CCL3-
mediated transmigration of human PBMCs, where R17 and M3
proved inhibitory while R7 did not (Fig. 3B).
R17 blocks chemokine-mediated calcium release. Activation
of chemokine receptor signaling leads to calcium release from
endoplasmic reticulum stores resulting in elevated levels of cyto-
plasmic calcium (38). Changes in calcium levels upon chemokine
stimulation can be monitored in real time by Fura-2 dye-loaded
cells. Previous experiments with MHV68 M3 revealed that it is an
effective Ca2	 flux inhibitor for several distinct chemokines that it
engages (39). We have tested the ability of R17 to inhibit transient
increase in intracellular calcium induced by hCCL2 in THP-1
cells. When added in 10-fold molar excess, R17 effectively dimin-
ishes CCL2-mediated calcium flux, albeit not as effectively as M3,
which forms significantly more stable complexes with CCL2 (Fig.
3C). The addition of a negative-control protein, MR-1 (32),
showed no changes in CCL2-mediated calcium mobilization. To-
gether with the transmigration assays, these data suggest that R17
might function as an inhibitor of CC chemokine signaling.
R17 interacts with cell surface GAGs. To function properly,
chemokines need to interact with their cognate G protein-coupled
receptor as well as glycosaminoglycans (GAGs) on extracellular
surfaces where they establish their gradients (9, 40). The viral
chemokine binding proteins described to date have been shown to
interfere with chemokine-GPCR interactions, chemokine-GAG
interactions, or both (8). To assess the ability of R17 to block
chemokine-GAG interactions, we conducted cell surface binding
and competition assays. CHOK1 cells, rich in heparan and chon-
droitin sulfates, are readily stained with randomly biotinylated
CCL2 and CCL3, while the analogous flow cytometry experiments
carried out using the GAG-deficient CHO745 cell line (41) result
in minimal background staining (Fig. 4). As we previously re-
ported, M3 was effective in blocking the interaction between
CCL2 and cell surface GAGs (Fig. 4) (15). It is important to note
that complete inhibition of CCL2-GAG interactions by M3 was
evident when a BirA-tagged version of CCL2 was used in contrast
to the randomly biotinylated CCL2 used in the experiments de-
scribed here (15).
Surprisingly, when we preincubated biotinylated CCL2 or
CCL3 with a 5-fold molar excess of R17, we observed a dramatic
increase in chemokine staining of CHOK1 but not CHO745 cells
(Fig. 4). To address a potential mechanism through which R17
was able to enhance chemokine cell staining, we examined the
ability of biotinylated R17 alone to stain CHOK1 and CHO745
cells. We discovered that biotinylated R17 readily stains CHOK1
but not CHO745 cells, suggesting that R17 specifically interacts
with cell surface GAGs (Fig. 5). This result not only identified an
additional binding partner for R17 but also enabled a clearer in-
terpretation of the enhanced chemokine cell staining mediated by
R17. We propose that because R17 engages both chemokines and
cell surface GAGs, it is able to trap chemokines at the cell surface,
resulting in our observed increase in CHOK1 staining by biotin-
ylated CCL2 and CCL3.
R17 interacts with GAGs via determinants distinct from
chemokine binding. Our flow cytometry experiments suggest
that R17 can simultaneously engage cell surface GAGs and chemo-
kines. Examination of the amino acid sequence of R17 reveals the
presence of two BBXB motifs known to be important for GAG
binding in a number of different proteins (42, 43). We therefore
created two variants of R17 through site-directed mutagenesis,
R17GAG1, in which residues 29 to 32 RKDR (BBXB) were mutated
to EDDE, and R17GAG2, where residues 333 to 337 KGRRK
(BXBBB) were mutated to DGEED. When tested, neither biotin-
ylated R17 variant was capable of staining CHOK1 cells, suggest-
ing that both BBXB motifs are indeed critical for GAG binding
(Fig. 5A). However, both R17GAG1 and R17GAG2 bound CCL2 and
CCL3 with binding parameters comparable to those observed for
wild-type R17 (Fig. 5B). Thus, the R17 determinants for cell sur-
face GAG binding are distinct from those mediating the high-
affinity binding of CC chemokines.
DISCUSSION
Here, we describe the identification and characterization of a
novel soluble chemokine binding protein, R17, encoded by
RHVP. The mature secreted R17 protein is composed of 412 res-
idues with six potential disulfide bridges and three Asn-linked
glycosylation sites. R17 displays no appreciable amino acid se-
quence similarity to any other viral or cellular protein. In contrast
FIG 4 R17 enhances chemokine cell surface binding. Flow cytometry analysis of CHOK1 (A) and CHO745 (GAG-deficient) (B) cells stained by 10 nM
biotinylated mCCL2 and mCCL3 in the presence or absence of either 100 nM R17 or 100 nM M3.
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to the highly promiscuous chemokine binding of MHV68 M3
(39), R17 binds selectively to CC chemokines and XCL1. Our SPR
studies indicate that R17 binds CCL2, CCL8, CCL9, and CCL20
with affinities ranging from 1 to 80 nM, rapid association kinetics,
and half-lives of 2 to 35 s. R17 engages another group of chemo-
kines (CCL3, CCL4, CCL5, CCL24, and XCL1) with extremely
long half-lives that are difficult to quantitate but we estimate as
greater than 10 min. As such, the chemokine binding properties of
R17 closely resemble those of the vCCI decoy receptor encoded by
ectromelia, EVM1, which forms moderately fast dissociating
complexes with CCL2 and highly kinetically stable complexes
with CCL3 and CCL5 (20). The difference in the off rates among
two groups of R17-chemokine complexes is interesting and is
likely to reflect variation in specific amino acids important for this
interaction. For example, structural inspection of CCL2, CCL3,
and CCL5 chemokines together with mutagenesis data indicate
distinct positioning of basic residues thought to mediate GAG
binding. While CCL3 and CCL5 have BBXB motifs localized to the
40’s loop (loop connecting beta strands 2 and 3), GAG binding
residues on CCL2 have been mapped to R18, K19, and R24 of the
N-terminal loop (20’s loop) (44).
Similarly to MHV68 M3 and poxvirus vCCIs, RHVP R17 ap-
pears to operate as a true decoy receptor, blocking the ability of
chemokines to activate their host receptors (Fig. 6). Our data in-
dicate that R17 capably inhibits both CCL2- and CCL3-driven
transmigration despite the fact that CCL3 is a much tighter binder.
But our comparison of the abilities of R17 and M3 to block CCL2-
mediated calcium release indicates a greater potency for M3,
which binds this chemokine with a significantly longer half-life
than R17.
In addition to chemokine binding, R17 also tightly associates
with cell surface GAGs. Indeed, our flow cytometry experiments
indicate that R17 can dramatically increase the association of
chemokines with cell surfaces. We inspected the primary sequence
of R17, finding two basic BBXB motifs that are commonly found
in GAG binding proteins, including many chemokines. R17 vari-
ants lacking either BBXB motif do not bind cell surface GAGs, and
chemokine binding experiments with these variants indicate that
the R17 chemokine and GAG binding sites are independently po-
sitioned. As such, the increased chemokine cell surface association
we observed can be explained by the high-affinity binding of
chemokines to GAG-associated R17. In this regard, R17 exhibits
similarity with myxoma virus MT-1 (vCCI) that has been shown
to interact with cell surface GAGs while simultaneously blocking
receptor-mediated chemokine signaling (45). In contrast, ec-
tromelia E163 binds both chemokines and GAGs, although unlike
R17 and MT-1, disruption of chemokine signaling by this protein
has not been observed (23).
The idea of using virally encoded decoy receptors to therapeu-
tically block chemokine signaling was introduced a few years ago
(46). For example, vCCI has been shown to diminish inflamma-
FIG 5 R17 interacts with cell surface GAGs at a site distinct from chemokine binding. (A) Flow cytometry analysis of CHOK1 and CHO745 cells stained by
biotinylated R17 and the BBXB mutants R17GAG1 and R17GAG2. (B) SPR binding analysis of the interaction of CCL2 and CCL3 with R17GAG1 and R17GAG2.
FIG 6 Sabotage of chemokine function by R17 and M3. Schematic diagram
illustrating R17- and M3-mediated disruption of chemokine binding to
GPCRs, M3-mediated disruption of chemokine-GAG interactions, and R17
association with cell surface GAGs.
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tion in allergen-induced asthma (47) and intraperitoneal injection
mouse models (48). MT-1 treatment was shown to alleviate vas-
cular pathology by inhibiting early monocyte and lymphocyte in-
filtration in vascular transplantation models (49). M3 has shown
promise as an anti-inflammatory therapeutic in several models,
including tumor rejection (50) and vascular injury (51). Islet-spe-
cific M3 expression can also prevent inflammatory recruitment,
islet destruction, and subsequent diabetes in mouse insulitis mod-
els (52). The discovery of R17 as a novel chemokine decoy receptor
with unique chemokine and GAG binding properties sets the stage
for future experiments evaluating its therapeutic potential in sim-
ilar experimental models.
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